Impact of Letermovir Prophylaxis for Cytomegalovirus Reactivation on Post-Transplant Outcomes 100 Days before and after Allogeneic Hematopoietic Cell Transplantation

被引：0

作者：

Takenaka, Katsuto ^{[1
]}

Fuji, Shigeo ^{[2
]}

Matsukawa, Toshihiro ^{[3
]}

Uchida, Naoyuki ^{[4
]}

Kobayashi, Takeshi ^{[5
]}

Tanaka, Masatsugu ^{[6
]}

Ara, Takahide ^{[7
,8
]}

Ikegame, Kazuhiro ^{[9
]}

Ozawa, Yukiyasu ^{[10
]}

Kanda, Yoshinobu ^{[11
]}

Sawa, Masashi ^{[12
]}

Maruyama, Yumiko ^{[13
]}

Fukuda, Takahiro ^{[14
]}

Nakamae, Hirohisa ^{[15
]}

Kimura, Takafumi ^{[16
]}

Ogata, Masao ^{[17
]}

Seo, Sachiko ^{[18
]}

Atsuta, Yoshiko ^{[19
,20
]}

Matsuo, Keitaro ^{[21
]}

Nakasone, Hideki ^{[22
]}

机构：

[1] Ehime Univ, Dept Hematol Clin Immunol & Infect Dis, Grad Sch Med, Toon, Japan

[2] Osaka Int Canc Ctr Inst, Osaka, Japan

[3] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[4] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Tokyo, Japan

[6] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa, Japan

[7] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[8] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[9] Hyogo Med Univ Hosp, Dept Hematol, Nishinomiya, Hyogo, Japan

[10] Nagoya Daiichi Hosp, Japanese Red Cross Aichi Med Ctr, Nagoya, Aichi, Japan

[11] Jichi Med Univ, Dept Med, Div Hematol, Shimotsuke, Tochigi, Japan

[12] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Aichi, Japan

[13] Univ Tsukuba Hosp, Dept Hematol, Tsukuba, Ibaraki, Japan

[14] Natl Canc Ctr, Dept Hematopoiet Stem Cell Transplantat, Tokyo, Japan

[15] Osaka Metropolitan Univ Hosp, Dept Hematol, Osaka, Japan

[16] Japanese Red Cross Kinki Block Blood Ctr, Preparat Dept, Osaka, Japan

[17] Oita Univ Hosp, Dept Hematol, Yufu City, Japan

[18] Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan

[19] Aichi Med Univ, Sch Med, Dept Registry Sci Transplant & Cellular Therapy, Nagakute, Aichi, Japan

[20] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagakute, Aichi, Japan

[21] Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi, Japan

[22] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Saitama, Japan

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180906

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era
Sassine, Joseph
Khawaja, Fareed
Shigle, Terri Lynn
Handy, Victoria
Foolad, Farnaz
Aitken, Samuel L.
Jiang, Ying
Champlin, Richard
Shpall, Elizabeth
Rezvani, Katy
Ariza-Heredia, Ella J.
Chemaly, Roy F.
CLINICAL INFECTIOUS DISEASES, 2021, 73 (08) : 1346 - 1354
[42] Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation
Tan, Carrie A.
Palen, Lauren
Su, Yiqi
Li, Yuxuan
Gennarelli, Renee L.
Perales, Miguel-Angel
Cohen, Nina
Papanicolaou, Genovefa A.
Shah, Gunjan L.
Seo, Susan K.
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (08): : 792e1 - 792e12
[43] Efficacy and Pharmacoeconomic Impact of Letermovir for CMV Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
Merchant, Shelby Lorraine
Gatwood, Katie S.
Satyanarayana, Gowri
Byrne, Michael T.
Kassim, Adetola A.
Jagasia, Madan
Savani, Bipin
Engelhardt, Brian G.
Culos, Kathryn Ann A.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[44] Vancomycin use and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation
Zhang, Shijia
Shanley, Ryan
Weisdorf, Daniel J.
Rashidi, Armin
BLOOD ADVANCES, 2020, 4 (12) : 2640 - 2643
[45] Clinical Observation of Sequential Prophylaxis with Letermovir Injection and Tablets for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Pang, Aiming
Zheng, Yawei
Chen, Shulian
Shen, Yuyan
Zhao, Xiaoli
Ni, Xiaofei
Zhang, Lining
Wang, Jiali
Cao, Wenbin
Chen, Xin
Cao, Yigeng
Jiang, Erlie
BLOOD, 2024, 144 : 7292 - 7292
[46] Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
Lin, Andrew
Flynn, Jessica
DeRespiris, Lauren
Figgins, Bradley
Griffin, Meagan
Lau, Carmen
Proli, Anthony
Devlin, Sean M.
Cho, Christina
Tamari, Roni
Jakubowski, Ann A.
Papadopoulos, Esperanza B.
Giralt, Sergio A.
Perales, Miguel-Angel
Seo, Susan K.
Shaffer, Brian
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (01):
[47] Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus
Solh, Melhem
Solomon, Scott R.
Zhang, Xu
Morris, Lawrence E.
Bachier-Rodriguez, Lizamarie
Holland, H. Kent
Bashey, Asad
BLOOD, 2022, 140 : 4745 - 4746
[48] Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation
Kaur, Raena
Purtill, Duncan
Cooney, Julian
Cannell, Paul
Wright, Matthew
Copeland, Tandy-Sue
McGuire, Matthew
Boan, Peter
TRANSPLANT INFECTIOUS DISEASE, 2023, 25
[49] Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes
Yuhua Ru
Xiang Zhang
Tiemei Song
Yiyang Ding
Ziling Zhu
Yi Fan
Yang Xu
Aining Sun
Huiying Qiu
Zhengming Jin
Xiaowen Tang
Yue Han
Zhengzheng Fu
Suning Chen
Xiao Ma
Feng Chen
Jia Chen
Depei Wu
Bone Marrow Transplantation, 2020, 55 : 1754 - 1762
[50] Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review
Sepassi, Aryana
Saunders, Ila M.
Bounthavong, Mark
Taplitz, Randy A.
Logan, Cathy
Watanabe, Jonathan H.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2023, 63 (04) : 1138 - 1149

← 1 2 3 4 5 →